Background—In hypertrophic cardiomyopathy (HCM), heart transplant has been
predominantly confined to patients with systolic dysfunction. An underappreciated HCM …

Background—Heart transplant is a treatment option for selected patients with hypertrophic
cardiomyopathy (HCM). However, the prevalence, clinical profile, and outcome of this …

Background End-stage (ES) hypertrophic cardiomyopathy (HCM) has been considered a
particularly grim and unfavorable disease complication, associated with substantial …

Heart transplantation (HT) is the sole therapeutic option for selected patients with
hypertrophic cardiomyopathy (HC) and refractory heart failure. However, the results of HT …

Background: Left ventricular outflow tract gradients are absent in an important proportion of
patients with hypertrophic cardiomyopathy (HCM). However, the natural course of this …

Heart transplant has become an increasingly important option for patients with end-stage
nonobstructive hypertrophic cardiomyopathy (HC). However, clinical details related …

Cardiac transplantation is a treatment option for patients with hypertrophic cardiomyopathy
(HC) who developed refractory heart failure and/or intractable arrhythmia. However, the …

Aims Hypertrophic cardiomyopathy (HCM) is an important cause of heart failure-related
disability over a wide range of ages. Profiles of severe progressive heart failure symptoms …

Objectives The significance of the progression of systolic and diastolic dysfunctions in
hypertrophic cardiomyopathy (HCM) is still an open issue. We sought to evaluate the clinical …

Introduction Heart failure (HF) in hypertrophic cardiomyopathy (HCM) is associated with high
morbidity and mortality. Predictors of HF, in particular the role of myocardial fibrosis and …